Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a humanized IgG1 monoclonal antibody that targets IL-17? and prevents the interaction with its receptor (IL-17R), thus blocking IL-17? mediated inflammatory and immune responses. IL-17? is a pro-inflammatory cytokine that plays an important role in inflammatory diseases such as psoriatic arthritis and ankylosing spondylitis (AS). In the heavy chain of the original antibody, VH variable domain is replaced with the VHH domain of Lama glama that possesses a long complementary determining region (CDR-H3) that allows the antibody to bind IL-17 with a higher affinity. The original antibody-drug has been approved to treat moderate-to-severe plaque psoriasis. Additionally, the drug is undergoing clinical trials to treat ankylosing spondylitis (AS).
Biovision | A2206 | Anti-IL-17? (Netakimab), Human IgG1 Antibody DataSheet
Antibody Target: IL-17?
Target Alternative Name: BCD-085, BCD085, BCD 085, IL17a, IL17, CTLA8, IL-17, CTLA-8, IL-17A
Tag Line: The biosimilar is a humanized monoclonal antibody that targets IL-17? and inhibits IL-17? mediated inflammatory responses
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities:
Immunogen Sequence: Human IL-17?
Accession #:
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
